Stock 4132 GOLDEN BIOTECHNOLOGY CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

News Golden Biotechnology Corporation

Equities

4132

TW0004132006

End-of-day quote Taipei Exchange
Other stock markets
 06:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
29.05 TWD -0.85% Intraday chart for Golden Biotechnology Corporation +1.04% -25.99%
Jan. 18 Golden Biotechnology Corp. Unveils the Findings of Its Phase II Clinical Trial Investigating Antroquinonol CI
2023 Golden Biotechnology Corporation Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ASCO GI 2024, Golden Biotech's Antroquinonol Shows Significantly Prolonged Survival in Untreated Metastatic Pancreatic Cancer Patients
AQ
Golden Biotechnology Corp. Unveils the Findings of Its Phase II Clinical Trial Investigating Antroquinonol
CI
Golden Biotechnology Corporation Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Golden Biotech Announces Positive Results with Longer Survival Compared with Standard Treatments from Interim Analysis of Phase 2 Trial for Antroquinonol as 1st Line Treatment for Stage 4 Metastatic Pancreatic Cancer
CI
Golden Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Golden Biotechnology Corporation Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Golden Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2021
CI
Golden Biotechnology Corporation Announces Topline Results from Unblinded COVID-19 Trial for Oral New Drug Antroquinonol in Hospitalized Mild, Moderate and Severe Patients
CI
Golden Biotechnology Corporation Receives Antroquinonol Oral Covid-19 New Drug Trial Got Green Light from the FDA to Extend Recruiting Severe Covid-19 Patients
CI
Golden Biotechnology Corporation Reports Earnings Results for the Half Year Ended June 30, 2021
CI
Golden Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2020
CI
GoldenBiotech's New Drug Antroquinonol Trial Receives Positive Response from DMC Review and Licenses for 4 Countries
CI
Golden Biotechnology Corp. Reports New Drug Trial of Antroquinonol -Outperforms Listing Drugs in Relapsed Acute Myeloid Leukemia
CI
Golden Biotechnology Corporation Reports Earnings Results for the Half Year Ended June 30, 2020
CI
Anti-viral and Anti-Inflammatory Response: GoldenBiotech's Antroquinonol Receives FDA Approval on COVID-19 Phase 2 Trial in USA
AQ
Golden Biotechnology Corp. Announces it's Antroquinonol Receives FDA Approval on COVID-19 Phase 2 Trial in USA
CI
Golden Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2019
CI
Golden Biotechnology Corporation Reports Earnings Results for the Half Year Ended June 30, 2019
CI
Golden Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2018
CI
Golden Biotechnology Corporation(GTSM:4132) added to S&P Global BMI Index
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4132 Stock
  4. News Golden Biotechnology Corporation